Genzyme patents new SLC6A19 inhibitors for phenylketonuria
Jan. 27, 2025
Genzyme Corp. (Sanofi Genzyme) has disclosed sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, among others.